Home » Posts tagged with » Clay Siegall
Seattle Genetics signs $4.4bn worth oncology deals with Merck

Seattle Genetics signs $4.4bn worth oncology deals with Merck

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]

September 14, 2020No CommentRead More

Takeda bags ADCETRIS EC approval for CD30+ Stage IV Hodgkin lymphoma

February 11, 2019 No Comment
Takeda bags ADCETRIS EC approval for CD30+ Stage IV Hodgkin lymphoma

ADCETRIS EC approval : The European Commission (EC) has expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to cover treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients. ADCETRIS is an antibody-drug conjugate (ADC) that targets CD30, which is a defining marker of […]

Continue reading …

Seattle Genetics’ Adcetris gets FDA approval for peripheral T-cell lymphoma

November 18, 2018 No Comment
Seattle Genetics’ Adcetris gets FDA approval for peripheral T-cell lymphoma

Adcetris FDA approval : Seattle Genetics has secured new approval from the US Food and Drug Administration (FDA) for its monoclonal antibody Adcetris (brentuximab vedotin), which is in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) for the treatment of certain types of peripheral T-cell lymphoma (PTCL). Adcetris FDA approval for PTCL in combination with CHP […]

Continue reading …